glp-1/gip agonist New strategies for the treatment of obesity and metabolic dysfunctions GIPR/GLP-1R dual agonist therapies for
Description
And a complete daily protocol you can start using today
The oral form of semaglutide, Rybelsus , further expands its reach, offering a non-injectable option, which appeals to a larger subset of patients who are hesitant about injections
They do this by: triggering the pancreas to release more insulin stopping the liver from making too much glucose slowing down digestion, to feel fuller for longer They're usually injectable medications, taken daily or weekly
Foundayo was FDA-approved in April 2026 and is available at Endocare in Dubai and Abu Dhabi
